A multicenter,randomized,double blind,placebo-controlled clinical trial of DL-3-n-butylphthalide in treatment of amyotrophic lateral sclerosis  

作　　者：Mingsheng Liu Xiaoli Yao Xusheng Huang Huifang Shang Dongsheng Fan Jia He Liying Cui the Chinese ALS Study Group 

机构地区：[1]Department of Neurology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China [2]Department of Neurology,The First Affiliated Hospital,Sun Yat-sen University,Guangzhou,Guangdong 510006,China [3]Department of Neurology,Chinese PLA General Hospital,Beijing 100853,China [4]Department of Neurology,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China [5]Department of Neurology,Peking University Third Hospital,Beijing 100191,China [6]Department of Health Statistics,Faculty of Health Service,Naval Medical University,Shanghai 200433,China [7]不详

出　　处：《Chinese Medical Journal》2023年第3期354-356,共3页中华医学杂志（英文版）

基　　金：supported by CSPC NBP Pharmaceutical Co.Ltd.

摘　　要：To the Editor:DL-3-n-butylphthalide(NBP)is a synthetic drug based on a component extracted from seeds of Apium graveolens Linn.(Chinese celery).It reportedly has protective effects in amyotrophic lateral sclerosis(ALS)model mice.[1]A randomized,double-blind,placebocontrolled trial was performed at 19 ALS clinical centers of the Chinese ALS association.All patients provided written informed consent.The Ethics Committee of Peking Union Medical College Hospital approved the study protocol(No.S621)and all patients signed informed consent.All centers followed the same research protocol.

关 键 词：clinical amyotrophic protective 

分 类 号：R744.8[医药卫生—神经病学与精神病学]